# Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

> **NCT06027983** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 36 (estimated)

## Conditions studied

- HER2+ Advanced Breast Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** Chimeric receptor T-cells + Trastuzumab
- **DRUG:** Fludarabine and Cyclophosphosphamide

## Key facts

- **NCT ID:** NCT06027983
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06027983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06027983, "Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06027983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*